Recordati’s OTC Sales Lifted by Acquisitions And Italy
Executive Summary
Italy's Recordati enjoyed strong growth in its home market and abroad, lifting OTC group sales in 2019.
You may also be interested in...
EMA Reviewing Two Centralised Switch Applications
Teva's Ratiopharm and Italy's Recordati have submitted applications to switch drugs from prescription-to-OTC status through EMA's centralised procedure. Given only four products have been switched centrally to date, a double reclassification would be unprecedented.
Italy's Recordati Takes Slice of French OTC Market With Laboratoires Tonipharm
Recordati's new private-equity owners make their first move to strengthen the Italian firm's position in Europe's OTC market by grabbing Paris-based Laboratoires Tonipharm and its leading Ginkor brand.
Timely Acquisition Keeps Germany's Dermapharm Growing
With its Branded Pharmaceuticals division negatively impacted by the end of the COVID-19 pandemic, the timely acquisition of supplements firm Arkopharma ensured Dermapharm recorded double-digit sales growth in 2023.